Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

BACKGROUND: We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear. METHODS: The neoadjuvant GeparQuinto tr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Witzel, I, Loibl, S, von Minckwitz, G, Eidtmann, H, Fehm, T, Khandan, F, Schmatloch, S, Hauschild, M, Bischoff, J, Fasching, P A, Mau, C, Schem, C, Rack, B, Meinhold-Heerlein, I, Liedtke, C, Karn, T, Huober, J, zu Eulenburg, C, Issa-Nummer, Y, Untch, M, Müller, V
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2012
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3464767/
https://ncbi.nlm.nih.gov/pubmed/22892393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.353
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller